在患有轻度至中度阿尔茨海默病的亚洲参与者中,阿尔茨海默病评估电池的验证

American journal of neurodegenerative disease Pub Date : 2014-12-05 eCollection Date: 2014-01-01
Joan Hq Shen, Qi Shen, Holly Yu, Jin-Shei Lai, Jennifer L Beaumont, Zhenxin Zhang, Huali Wang, Seong Yoon Kim, Christopher Chen, Timothy Kwok, Shuu-Jiun Wang, Dong Young Lee, John Harrison, Jeffrey Cummings
{"title":"在患有轻度至中度阿尔茨海默病的亚洲参与者中,阿尔茨海默病评估电池的验证","authors":"Joan Hq Shen,&nbsp;Qi Shen,&nbsp;Holly Yu,&nbsp;Jin-Shei Lai,&nbsp;Jennifer L Beaumont,&nbsp;Zhenxin Zhang,&nbsp;Huali Wang,&nbsp;Seong Yoon Kim,&nbsp;Christopher Chen,&nbsp;Timothy Kwok,&nbsp;Shuu-Jiun Wang,&nbsp;Dong Young Lee,&nbsp;John Harrison,&nbsp;Jeffrey Cummings","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>There is a lack of validated tools for assessing Alzheimer's disease (AD) across Asia. This study evaluates the psychometric properties of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Neuropsychological Test Battery (NTB) in Asian participants. Participants with mild to moderate AD (n=251) and healthy controls (n=51) from Mainland China, Taiwan, Singapore, Hong Kong, and South Korea completed selected instruments at several time points. Test-retest reliability was better than 0.70 for all tests. AD participants performed significantly more poorly than controls on every score. Within the AD group, greater disease severity corresponded to significantly poorer performance. The AD group test performance worsened over time and there was a trend for worse performance in AD compared to healthy controls over time. The ADAS-Cog, DAD, and NTB are reliable, valid, and responsive measures in this population and could be used for clinical trials across Asian countries/regions. </p>","PeriodicalId":72170,"journal":{"name":"American journal of neurodegenerative disease","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299719/pdf/ajnd0003-0158.pdf","citationCount":"0","resultStr":"{\"title\":\"Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease.\",\"authors\":\"Joan Hq Shen,&nbsp;Qi Shen,&nbsp;Holly Yu,&nbsp;Jin-Shei Lai,&nbsp;Jennifer L Beaumont,&nbsp;Zhenxin Zhang,&nbsp;Huali Wang,&nbsp;Seong Yoon Kim,&nbsp;Christopher Chen,&nbsp;Timothy Kwok,&nbsp;Shuu-Jiun Wang,&nbsp;Dong Young Lee,&nbsp;John Harrison,&nbsp;Jeffrey Cummings\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>There is a lack of validated tools for assessing Alzheimer's disease (AD) across Asia. This study evaluates the psychometric properties of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Neuropsychological Test Battery (NTB) in Asian participants. Participants with mild to moderate AD (n=251) and healthy controls (n=51) from Mainland China, Taiwan, Singapore, Hong Kong, and South Korea completed selected instruments at several time points. Test-retest reliability was better than 0.70 for all tests. AD participants performed significantly more poorly than controls on every score. Within the AD group, greater disease severity corresponded to significantly poorer performance. The AD group test performance worsened over time and there was a trend for worse performance in AD compared to healthy controls over time. The ADAS-Cog, DAD, and NTB are reliable, valid, and responsive measures in this population and could be used for clinical trials across Asian countries/regions. </p>\",\"PeriodicalId\":72170,\"journal\":{\"name\":\"American journal of neurodegenerative disease\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-12-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299719/pdf/ajnd0003-0158.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of neurodegenerative disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2014/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of neurodegenerative disease","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

整个亚洲缺乏评估阿尔茨海默病(AD)的有效工具。本研究评估了亚洲参与者阿尔茨海默病评估量表-认知亚量表(ADAS-Cog)、痴呆症残疾评估(DAD)和神经心理测试组(NTB)的心理测量特性。来自中国大陆、台湾、新加坡、香港和韩国的轻至中度AD患者(n=251)和健康对照(n=51)在几个时间点完成了选择的工具。所有测试的重测信度均大于0.70。AD参与者在每一项上的表现都明显比对照组差。在AD组中,疾病严重程度越高,表现越差。随着时间的推移,AD组的测试表现越来越差,与健康对照组相比,AD组的表现有越来越差的趋势。ADAS-Cog、DAD和NTB在这一人群中是可靠、有效和反应灵敏的措施,可用于亚洲国家/地区的临床试验。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease.

Validation of an Alzheimer's disease assessment battery in Asian participants with mild to moderate Alzheimer's disease.

There is a lack of validated tools for assessing Alzheimer's disease (AD) across Asia. This study evaluates the psychometric properties of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Neuropsychological Test Battery (NTB) in Asian participants. Participants with mild to moderate AD (n=251) and healthy controls (n=51) from Mainland China, Taiwan, Singapore, Hong Kong, and South Korea completed selected instruments at several time points. Test-retest reliability was better than 0.70 for all tests. AD participants performed significantly more poorly than controls on every score. Within the AD group, greater disease severity corresponded to significantly poorer performance. The AD group test performance worsened over time and there was a trend for worse performance in AD compared to healthy controls over time. The ADAS-Cog, DAD, and NTB are reliable, valid, and responsive measures in this population and could be used for clinical trials across Asian countries/regions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信